Kusajili – Centralise les essais cliniques mondiaux

Résultat de votre recherche par promoteur : PIERRE FABRE MEDICAMENT (Represented by: Institut de Recherche Pierre Fabre)

Femme et Homme Max 99 ans
PIERRE FABRE MEDICAMENT (Represented by: Institut de Recherche Pierre Fabre) MAJ Il y a 4 ans

A 4-week double-blind placebo-controlled pilot study, evaluating niacin-induced flushing and lipid parameter effects of V0002 CA 1g 3 capsules/day associated with Niaspan® (from 375 mg to 1000 mg) in addition to usual care statin, in patients suffering from dyslipidemia with uncontrolled elevated triglycerides To assess efficacy of V0002 CA 1 g at 3 capsules /day on preventing niacin-induced flushing promoted by Niaspan® administration

Pays Aucun
Organes Aucun
Spécialités Aucune

unknown

Plus d'informations